Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $6.98 USD
Change Today +0.24 / 3.56%
Volume 876.0K
ARWR On Other Exchanges
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

arrowhead research corp (ARWR) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/1/14 - $18.87
52 Week Low
12/4/14 - $4.95
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

arrowhead research corp (ARWR) Related Businessweek News

No Related Businessweek News Found

arrowhead research corp (ARWR) Details

Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. The company’s principal product candidates comprise ARC-520, an RNAi-based therapeutic that is in Phase IIa clinical trial to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Its platform technology include Dynamic Polyconjugate platform, an RNAi delivery system that addresses multiple organ systems and cell types. The company is also involved in the development of Adipotide, which is in phase I clinical trial for the treatment of obesity and metabolic disorders; and CRLX-101 that is in phase II clinical trial to treat various cancer types, including relapsed renal cell carcinoma, relapsed ovarian cancer, and non-metastatic rectal cancer. It has research collaboration and license agreement with Shire AG to develop and commercialize targeted peptide-drug conjugates. The company was formerly known as InterActive Group, Inc. Arrowhead Research Corporation was incorporated in 1989 and is headquartered in Pasadena, California.

81 Employees
Last Reported Date: 11/25/14
Founded in 1989

arrowhead research corp (ARWR) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $543.6K
Chief Financial Officer
Total Annual Compensation: $293.4K
Chief Operating Officer
Total Annual Compensation: $384.2K
Vice President of Strategy & Program Manageme...
Total Annual Compensation: $222.8K
Chief Scientific Officer
Total Annual Compensation: $226.4K
Compensation as of Fiscal Year 2014.

arrowhead research corp (ARWR) Key Developments

Arrowhead Research Corp., Novartis - M&A Call

To consider the acquisition of Novartis entire RNAi research and development portfolio and associated assets

Arrowhead Research Corp. Presents at Barclays Global Healthcare Conference, Mar-11-2015 01:35 PM

Arrowhead Research Corp. Presents at Barclays Global Healthcare Conference, Mar-11-2015 01:35 PM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States. Speakers: Christopher R. Anzalone, Chief Executive Officer, President, Director, Chief Executive Officer of Calando, Chief Executive Officer of Tego, Chief Executive Officer of Nantope, Chief Executive Officer of Leonardo and Chief Executive Officer of Ablaris Therapeutics.

Arrowhead Research Corp. Begins Phase 1 Trial of ARC-AAT for Treatment of Liver Disease Associated with Alpha-1 Antitrypsin Deficiency

Arrowhead Research Corporation announced that it has initiated dosing in a Phase 1 clinical trial of ARC-AAT, the company s candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disorder that severely damages the liver and lungs of affected individuals. Trial initiation followed successful completion of the Clinical Trial Notification (CTN) regulatory process in Australia. The study will be conducted in two parts, with Part A in healthy volunteers and Part B in patients with AATD. The primary objectives of the study are to determine the safety and tolerability of escalating doses of ARC-AAT, evaluate the pharmacokinetics, and determine the effect on circulating levels of alpha-1 antitrypsin. Initial data from this study is expected in late 2015. The ARC-AAT Phase 1 trial is the first human study of an RNAi therapeutic against liver disease associated with AATD, which has no current treatment options, short of liver transplant. ARC-AAT is its second clinical candidate using the DPC delivery system, after ARC-520 targeting the hepatitis B virus, and it is the first candidate that targets an endogenous gene to enter human trials. The Phase 1 trial is a multi-center, randomized, placebo-controlled, double-blind, single dose-escalation first-in-human study to evaluate the safety, tolerability, pharmacokinetics of ARC-AAT and the effect on circulating alpha-1 antitrypsin (AAT) levels. The study plans to enroll in dose cohorts of six participants each, with participants randomized at a ratio of 2:1 (active:placebo) to receive a single intravenous injection of either ARC-AAT or placebo (normal saline). The study will consist of two parts, with Part A planned to be conducted in healthy volunteers and Part B planned to be conducted in patients with PiZZ genotype AATD. In Part A, dose escalation will proceed until the achievement of certain target knockdown parameters. When these AAT knockdown parameters are achieved, dose escalation in healthy volunteers (Part A) is planned to stop and dosing in patients with AATD (Part B) is planned to begin at the high dose level used in Part A and then dose escalation will proceed. The whole Alpha-1 community is excited to see this landmark clinical trial begin for Alpha-1 liver disease. ARC-AAT is the second clinical candidate to use Arrowhead s proprietary Dynamic Polyconjugate (DPC) delivery platform and includes an optimized RNAi-trigger design that contains an unlocked nucleobase analog (UNA) and various chemical modifications that enhance activity and substantially extend the duration of effect in non-clinical studies. Arrowhead previously reported data from these studies at an analyst day the company held in June 2014 and in a plenary presentation at the AASLD Liver Meeting in November 2014. Injection of ARC-AAT in transgenic mice expressing the inflammatory human Z-AAT protein resulted in prevention and reduction of Z-AAT globules and, importantly, liver inflammation. In primate studies, a 90% reduction of AAT in serum was observed after a single injection, which persisted for over ten weeks with greater than 80% knockdown observed at the six-week time point. Multi-dose studies in primates showed a sustained reduction of AAT with once every six weeks dosing. The goal of treatment with ARC-AAT is to reduce the hepatic production of Z-ATT, thereby preventing further accumulation of Z-AAT in the liver and potentially reversing pre-existing liver injury and fibrosis.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARWR:US $6.98 USD +0.24

ARWR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ARWR.
View Industry Companies

Industry Analysis


Industry Average

Valuation ARWR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,264.1x
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 842.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARROWHEAD RESEARCH CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at